A mechanistic approach for islet amyloid polypeptide aggregation to develop anti-amyloidogenic agents for type-2 diabetes

► Aggregation is the most riveting topic as most of the diseases are concerned with this phenomenon. ► In DM-2 a structural transition from physiological IAPP to pathological deposits takes place. ► IAPP aggregation (amyloidosis) takes place due to different acquired or inherited factors. ► This is compilation of multidisciplinary approaches to translate into new research opportunities. ► It will abet the communication between biologists and chemists to develop agents against amyloids.